NasdaqGS - Nasdaq Real Time Price USD
IDEAYA Biosciences, Inc. (IDYA)
As of 11:10 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
11,961.00
23,385.00
50,931.00
27,941.00
19,538.00
--
Operating Expense
203,346.00
157,814.00
113,433.00
78,209.00
54,882.00
--
Operating Income
-191,385.00
-134,429.00
-62,502.00
-50,268.00
-35,344.00
--
Net Non Operating Interest Income Expense
37,646.00
21,468.00
3,847.00
506.00
849.00
--
Other Income Expense
--
--
--
--
--
8.00
Pretax Income
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Net Income Common Stockholders
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Diluted NI Available to Com Stockholders
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Basic EPS
-2.18
-1.96
-1.42
-1.41
-1.40
--
Diluted EPS
-2.18
-1.96
-1.42
-1.41
-1.40
--
Basic Average Shares
69,621.55
57,519.93
41,444.70
35,252.44
24,721.78
--
Diluted Average Shares
69,621.55
57,519.93
41,444.70
35,252.44
24,721.78
--
Total Operating Income as Reported
-191,385.00
-134,429.00
-62,502.00
-50,268.00
-35,344.00
--
Total Expenses
203,346.00
157,814.00
113,433.00
78,209.00
54,882.00
--
Net Income from Continuing & Discontinued Operation
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Normalized Income
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Interest Income
37,646.00
21,468.00
3,847.00
506.00
849.00
--
Net Interest Income
37,646.00
21,468.00
3,847.00
506.00
849.00
--
EBIT
-191,385.00
-134,429.00
-62,502.00
-50,268.00
-35,344.00
--
EBITDA
-187,156.00
-130,421.00
-58,987.00
-47,236.00
-33,963.00
--
Reconciled Depreciation
4,229.00
4,008.00
3,515.00
3,032.00
1,381.00
--
Net Income from Continuing Operation Net Minority Interest
-153,739.00
-112,961.00
-58,655.00
-49,762.00
-34,495.00
--
Normalized EBITDA
-187,156.00
-130,421.00
-58,987.00
-47,236.00
-33,963.00
--
12/31/2019 - 5/23/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRUS Merus N.V.
51.81
-1.67%
PTGX Protagonist Therapeutics, Inc.
45.87
-2.34%
KROS Keros Therapeutics, Inc.
60.79
-0.75%
SYRE Spyre Therapeutics, Inc.
32.14
-1.89%
MLTX MoonLake Immunotherapeutics
48.41
-1.08%
TNGX Tango Therapeutics, Inc.
7.21
-3.35%
KRYS Krystal Biotech, Inc.
177.66
-0.85%
NRIX Nurix Therapeutics, Inc.
24.91
-0.56%
SWTX SpringWorks Therapeutics, Inc.
30.69
-0.90%
IMVT Immunovant, Inc.
29.07
-1.36%